INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 1996

In an open-label trial of 17 Alzheimer's patients, coenzyme nicotinamide adenine dinucleotide (NADH) was reported to improve cognitive dysfunction scores.

An open-label trial evaluated nicotinamide adenine dinucleotide (NADH) medication in 17 patients with dementia of the Alzheimer type for 8 to 12 weeks. All evaluated patients showed improvement in cognitive dysfunction, with Mini-Mental State Examination scores improving by a mean of 8.35 points (range: 6 to 14 points) and Global Deterioration Scale scores improving by a mean of 1.82 (range: 1 to 2 points). No side effects or adverse effects were reported during observation periods exceeding a year in some patients. The authors noted that this pilot study does not allow definitive conclusions and that a double-blind placebo-controlled study is necessary.

Study type
Open-label pilot trial
Who was studied
17 patients suffering from dementia of the Alzheimer type
What was measured
Cognitive dysfunction (Mini-Mental State Examination, Global Deterioration Scale), adverse effects

THE PAPER

Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.

Birkmayer JG. Ann Clin Lab Sci, 1996.

PubMed 8834355 ↗

Nutrients & adequacyBrain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.